INDIRECT TREATMENT COMPARISON OF USTEKINUMAB VERSUS OTHER BIOLOGICS IN MODERATE-TO-SEVERE CROHN'S DISEASE PATIENTS HAVING FAILED ANTI-TNF THERAPY ‒ A 1-YEAR TREATMENT SEQUENCE ANALYSIS INCLUDING DELAYED RESPONDERS
Laura Mesana 1
Maud Pacou 2
Dominik Naessens 3
Sheldon Sloan 4
Aline Gauthier 1
1 Amaris,London,United Kingdom
2 Amaris,Paris,France
3 Janssen Pharmaceutica,Beerse,Belgium
4 Janssen Global Services,Horsham,United States of America
Conference
25th UEG Week 2017
Citation
United European Gastroenterology Journal 2017; 5 (Supplement 1)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]
Social Sharing